Second Sight announces Argus II commercial progress, plans for expansion

PHILADELPHIA — Second Sight plans to expand the Argus II retinal prosthesis system for the treatment of retinitis pigmentosa into additional markets in the next several years, according to a speaker here.At the Wills Vision Research Center at Jefferson annual symposium, Anthony Moses, commercial vice president, Americas, at Second Sight, discussed the recent progress of the device — 3-year data results were announced in June — as well as its future market expansion.